We are pleased to announce that research conducted through a collaboration between TCG CREST’s CARE</strong> and IAI has been selected for an oral presentation at AiXLife 2026, to be held on April 17–18, 2026 at SASTRA Deemed University, Thanjavur, India.
The selected work, titled “Discovering EGFR-targeting drug resistance signatures in lung cancer using statistical machine learning,” will be presented by Ayan Das. The study focuses on understanding mechanisms of resistance to EGFR-targeted therapies in lung cancer through advanced statistical machine learning approaches applied to whole-exome sequencing (WES) data.
The research leverages an AI-driven, unsupervised analytical framework to identify compact and interpretable resistance signatures across multiple generations of EGFR tyrosine kinase inhibitors (EGFR-TKIs). By emphasizing interpretability alongside performance, the study addresses a critical challenge in translational AI for oncology—bridging complex genomic data with clinically actionable insights.
These findings contribute to the growing body of work aimed at enabling omics-guided prediction of patient response, with potential implications for treatment stratification and precision medicine in lung cancer care. The selection as an oral presentation underscores the relevance of the research to current challenges at the intersection of artificial intelligence, genomics, and healthcare.
This work represents a significant collaborative achievement involving TCG CREST’s CARE and IAI, with contributions from Ayan Das, Snigdha Patel, Anupama Goyal, and Shibasish Dasgupta. The team looks forward to engaging with the global research community at AiXLife 2026 and contributing to discussions on AI-enabled biomedical innovation.